TL;DR
This study investigates why a significant portion of cancer patients don't receive initial treatment, finding that nontreatment is more common in advanced stages, among older patients, and in those receiving recommendations from non-accredited facilities. The findings highlight that while patient characteristics play a role, provider and facility factors significantly influence these critical treatment decisions.
What Problem Does This Paper Address?
Despite advancements in cancer care, a notable percentage of patients diagnosed with cancer do not receive any form of initial treatment. The National Cancer Data Base (NCDB) suggests this rate is around 9.2%, but this data is limited to accredited cancer programs. This study aims to address this gap by investigating the rate and characteristics of patients who receive no first course of treatment using a more comprehensive data source that includes both accredited and non-accredited facilities. Understanding these patterns is crucial for identifying disparities and improving access to care.
Methods
The researchers utilized data from the Iowa Cancer Registry (ICR), which aims to capture all newly diagnosed cancer cases in Iowa residents, regardless of where they are diagnosed or treated. This provides a more population-representative dataset compared to the NCDB. They analyzed data from 2004 to 2010, focusing on patients who did not receive a first course of treatment within a year of diagnosis. Bivariate and multivariable logistic regression analyses were employed to identify patient and facility characteristics associated with nontreatment. The study also examined reasons for nontreatment, such as treatment being contraindicated, refused, or not planned.
Datasets
- Iowa Cancer Registry (ICR): This dataset served as the primary source of information, capturing all newly diagnosed invasive cancer cases in Iowa residents from 2004 to 2010. It includes over 113,000 patient cases.
- National Cancer Data Base (NCDB): Used for comparison, the NCDB provided data on nontreatment rates from COC-accredited cancer programs.
Key Insights and Ideas
- Higher Nontreatment Rate Than Expected: The ICR data revealed a nontreatment rate of 12.3%, significantly higher (48%) than the NCDB's reported rate of 8.3% for Iowa. This suggests that relying solely on accredited facilities underestimates the true extent of nontreatment.
- Advanced Stage and Age are Key Predictors: Nontreatment is strongly correlated with advanced cancer stages (Stage IV being six times more likely to be untreated than Stage I) and increasing patient age. This points to potential challenges in treatment delivery or decision-making for these vulnerable groups.
- Facility Accreditation Matters: Patients receiving initial treatment recommendations from non-accredited cancer programs were significantly more likely to not receive treatment. This highlights the importance of facility accreditation and the potential disparities in resources or care quality associated with non-accredited sites.
- Specific Cancers at Higher Risk: Certain cancers, like lung/bronchial cancers and low-grade non-Hodgkin lymphoma, showed higher rates of nontreatment. This could be due to the complexity of treatment, patient preferences, or physician recommendations for these specific disease types.
- Distance is Not the Primary Barrier: Interestingly, the study found no significant difference in travel distance between treated and nontreated patients, suggesting that geographical access, in terms of distance to facilities, is not the primary driver of nontreatment on average.
- Reasons for Nontreatment are Multifaceted: While a significant portion of nontreatment was due to no treatment being planned or contraindicated, a notable percentage involved treatment refusal or death before planned treatment. Surgery was the most commonly contraindicated or not administered modality.
Key Results
- The Iowa Cancer Registry (ICR) identified a nontreatment rate of 12.3% for first-course cancer treatment between 2004 and 2010.
- Nontreatment was 48% higher in the ICR data compared to the NCDB data for Iowa (12.3% vs. 8.3%).
- Patients with Stage IV cancer were six times more likely to not receive treatment compared to those with Stage I disease.
- Nontreatment increased significantly with age.
- Patients receiving recommendations from nonaccredited cancer programs were significantly more likely to not receive treatment.
- Lung/bronchial cancers and low-grade non-Hodgkin lymphoma had the highest nontreatment rates (around 20%).
- Approximately 9% of patients who did not receive treatment refused it.
Limitations and Future Work
The authors acknowledge several limitations:
- Timeframe for Nontreatment: Nontreatment in the ICR was defined as no treatment within one year of diagnosis. Patients who received treatment later might have been missed.
- Data Completeness and Documentation: While the ICR is robust, there's always potential for errors in medical record documentation.
- Missing Data: Crucial factors like insurance coverage and socioeconomic status were not available in the ICR data, preventing their inclusion in the analysis.
- Race/Ethnicity: Due to the predominantly white population in Iowa and the ICR data, race and ethnicity could not be analyzed.
- "Watchful Waiting" Ambiguity: The registry does not have a specific code for "watchful waiting" or "active surveillance," which might be a standard approach for certain cancers (e.g., early-stage prostate cancer, some non-Hodgkin lymphoma subtypes) and could be misclassified as nontreatment.
Future work should focus on elucidating additional factors and reasons for nontreatment, particularly exploring the interplay between patient preferences, provider decisions, and facility characteristics. Further research is needed to understand why newer, more tolerable treatments may not be adopted faster and to address the potential for slower adoption of new treatments.
Summary updated